tβri

Galunisertib (LY2157299) 是一种 TGF-β 受体 I 型 (TGF-βRI) 抑制剂 (IC50=56 nM)，具有选择性。Galunisertib 具有抗肿瘤活性，可与 PD-1 抑制剂联合治疗。

LY2109761 是一种新型选择性 TGF-β 受体 I II 型 (TβRI II) 双重抑制剂，Ki 分别为 38 nM 和 300 nM。

Azaribine (2;,3;,5;-Tri-O-acetyl-6-azauridine) 是一种乳清碱单磷酸脱羧酶 (OMPD) 抑制剂，具有广谱的抗病毒活性，可抑制病毒基因组复制和基因转录。Azaribine 可用于研究寨卡病毒 （ZIKV）感染，可用于研究银屑病关节炎和蕈样肉芽肿。

Tri-GalNAc-COOH 是唾液酸糖蛋白受体 (ASGPR) 的配体，常用于溶酶体靶向嵌合体 (LYTAC) 研究。

Methyl EudesMate 是由 Gallic acid 为原料合成得到，具有抗氧化活性，常用于生产磺胺增效剂中间体、甲氧苄氨嘧啶 (TMP)以及许多其它药物。

3,4,5-Trimethoxybenzoic acid (Gallic acid trimethyl ether) 是一种苯甲酸衍生物，可用作医药和有机合成中的砌块。

Uridine triacetate (RG 2133 triacetate) 是一种具有口服活性的 Uridine 前药。Uridine triacetate 能在肠道内迅速被吸收，在循环中迅速脱乙酰，生成游离尿苷。Uridine triacetate 可用于研究 5-氟尿嘧啶 (5-FU) 和卡培他滨的毒性，或早发性心脏或中枢神经系统 (CNS) 毒性。

Tricaprilin (Glycerol Tri-n-octanoate) 能够用于研究轻度到中度阿尔茨海默病患者，具有抗惊厥和植物代谢产物的活性。

5-Bromo-2’,3’,5’-tri-O-acetyluridine 是一种嘌呤核苷类似物，可用于探索探索改善阿尔茨海默氏症和帕金森氏症。

Chlorotrianisene (tri-p-anisylchloroethylene) 是长效、可口服、亲脂性高的合成三苯乙烯 (TPE) 衍生物和选择性雌激素受体调节剂，有雌激素活性，也有抗雌激素活性。它还有效抑制COX-1并抑制全血中的血小板聚集。

Tri-Salicylic acid 是一种和水杨酸具有相似性质的化合物。它对肥胖、炎症及心血管疾病具有潜在的研究价值。

Amino-Tri-(carboxyethoxymethyl)-methane, an ADC linker and PROTAC linker, is a cleavable PEG compound utilized for the synthesis of antibody-drug conjugates (ADCs)[1] and PEG-based PROTACs[2].

Azido-PEG4-amido-tri-(carboxyethoxymethyl)-methane is a PEG-based linker compound employed for the synthesis of PROTACs[1].

Azido-PEG4-Amido-tri-(t-butoxycarbonylethoxymethyl)-methane, a PEG-derived PROTAC linker, is employed for PROTAC synthesis[1].

Maleimido-tri(ethylene glycol)-propionic acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Maleimido-tri(ethylene glycol)-propionic acid is used for the preparation of neolymphostin-based ADC precursors for site-spec

Tri(Amino-PEG5-amide)-amine is a polyethylene glycol (PEG) derivative serving as a PEG-based proteolysis targeting chimera (PROTAC) linker, facilitating the synthesis of PROTACs[1].

Tri(t-butoxycarbonylethoxymethyl) ethanol, an alkyl ether-based PROTAC linker, is suitable for synthesizing PROTACs[1].

Amino-Tri-(m-PEG4-ethoxymethyl)-methane, a PEG-based PROTAC linker, serves as a valuable component for synthesizing PROTACs[1].

m-C-tri(CH2-PEG1-NHS ester) is a non-cleavable one-unit polyethylene glycol (PEG) linker employed for the synthesis of antibody-drug conjugates (ADCs)[1].

Tri(Amino-PEG3-amide)-amine is a polyethylene glycol (PEG)-derived linker employed for the synthesis of proteolysis-targeting chimeric molecules (PROTACs)[1].

Tri(Amino-PEG4-amide)-amine is a polyethylene glycol (PEG)-based linker compound utilized for the synthesis of proteolysis-targeting chimeras (PROTACs)[1].

Tri(Mal-PEG2-amide)-amine is a polyethylene glycol (PEG)-derived linker commonly employed for synthesizing proteolysis-targeting chimeras (PROTACs)[1].

Tri-(PEG1-C2-acid) is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Methyl Raloxifene 4'-(2,3,4-Tri-O-acetyl-β-D-glycopyranuronate) is a derivative compound of Raloxifene 4'-glucuronide, designed to resemble its structure and function.